# **AMENDMENTS TO THE CLAIMS**

Please amend the claims without prejudice, without admission, without surrender of subject matter, and without any intention of creating any estoppel as to equivalents, as follows.

# In the Claims:

# 1. (Currently amended)

A dosage form in film form for surface administration of at least one active ingredient and/or nutrient to a living creature comprising

at least one active ingredient-containing and/or nutrient-containing layer based on <u>in-situ</u> crosslinked hydrophilic polymers which comprises from 30% to 60% 20% to 60% by weight of glycerol as plasticizer, based on the total amount of crosslinked hydrophilic polymers.

## 2. (Cancelled)

# 3. (Previously presented)

The dosage form as claimed in claim 1, characterized in that hydroxypropylmethylcellulose was used as hydrophilic polymer.

#### 4. (Cancelled)

## 5. (Previously presented)

The dosage form as claimed in claim 1, characterized in that the hydrophilic polymer has been crosslinked with tannin and/or a crosslinked, optionally partially neutralized polyacrylic acid.

## 6. (Previously presented)

The dosage form as claimed in claim 1, characterized in that the active ingredient-containing and/or nutrient-containing layer comprises at least one active pharmaceutical ingredient or one nutrient.

-2- 00776416

# 7. (Original)

The dosage form as claimed in claim 6, characterized in that the active pharmaceutical ingredient is an active ingredient from the group of analgesics, antiallergics, antibiotics, antiemetics, antiseptics, antihistamines, antihypertensives, appetite suppressants, cardiac remedies, chemotherapeutic agents, enzymes, hormones, immunomodulators, inoculations, local anesthetics, psychoactive drugs, spasmolytics, virustatics, vitamins and cytostatics.

# 8. (Original)

The dosage form as claimed in claim 6, characterized in that the nutrient is a fertilizer.

# 9. (Previously presented)

The dosage form as claimed in claim 1, characterized in that it has one or more layers.

## 10. (Original)

The dosage form as claimed in claim 9, characterized in that it has at least one active ingredient-containing and/or nutrient-containing layer, one adhesive layer and/or one covering layer.

#### 11. (Original)

The dosage form as claimed in claim 10, characterized in that at least one active ingredient-containing and/or nutrient-containing layer has a concentration gradient of the active ingredient and/or of the nutrient.

#### 12. (Original)

The dosage form as claimed in claim 10, characterized in that the covering layer is impermeable for the active ingredient.

## 13. (Previously presented)

The dosage form as claimed in claim 1, characterized in that it is covered by a protective layer before application.

-3- 00776416

# 14. (Previously presented)

The dosage form as claimed in claim 1, characterized in that the living creature is a human or an animal.

## 15. (Previously presented)

The dosage form as claimed in claim 1, characterized in that the surface administration is a transmucosal or transdermal.

# 16. (Currently amended)

The dosage form as claimed in <u>claim 1</u> claim 2, characterized in that hydroxypropylmethylcellulose was used as hydrophilic polymer.

## 17. (Previously presented)

The dosage form as claimed in claim 16, characterized in that the hydrophilic polymer has been crosslinked with tannin and/or a crosslinked, optionally partially neutralized polyacrylic acid.

#### 18. (Previously presented)

The dosage form as claimed in claim 17, characterized in that it has at least one active ingredient-containing and/or nutrient-containing layer, one adhesive layer and/or one covering layer.

#### 19. (Previously presented)

The dosage form as claimed in claim 18, characterized in that at least one active ingredient-containing and/or nutrient-containing layer has a concentration gradient of the active ingredient and/or of the nutrient.

## 20. (Previously presented)

The dosage form as claimed in claim 18, characterized in that the covering layer is impermeable for the active ingredient.

-4- 00776416

# 21. (Previously presented)

The dosage form as claim in claim 20, characterized in that the ratio of hydrophilic polymer to crosslinker is from 2:1 to 5:1 by weight.

-5- 00776416